Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 9:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 697 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control powder Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess Safety of an Inactivated H5N1 Influenza Vaccine Administered in GelVac Nasal Powder to Healthy Young Adults

NCT01258062
View directory record Official record
Conditions
Phase 1 Safety Study of GelVac Nasal Powder H5N1 Influenza Vaccine
Interventions
GelVac™ nasal powder H5N1 influenza vaccine., Placebo
Drug
Lead sponsor
Alachua Government Services, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Oct 29, 2026, 9:23 PM EDT
Not listed Phase 2 Interventional

Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome

NCT05875948
View directory record Official record
Conditions
Hepatorenal Syndrome, Acute Kidney Injury
Interventions
R2R01, Terlipressin
Drug
Lead sponsor
River 2 Renal Corp.
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
7
States / cities
San Francisco, California • Atlanta, Georgia • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Oct 29, 2026, 9:23 PM EDT
Completed Phase 3 Interventional Results available

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation

NCT03930732
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Dupilumab SAR231893, Inhaled Corticosteroid, Inhaled Long-Acting Beta Agonist, Inhaled Long-Acting Muscarinic Antagonist, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years to 80 Years
Enrollment
939 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
51
States / cities
Andalusia, Alabama • Birmingham, Alabama • Dothan, Alabama + 46 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 29, 2026, 9:23 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent Chronic Kidney Disease (CKD) Patients With Hyperphosphataemia

NCT02688764
View directory record Official record
Conditions
Hyperphosphatemia
Interventions
PA21 (Velphoro®), Calcium Acetate (Phoslyra®)
Drug
Lead sponsor
Vifor Fresenius Medical Care Renal Pharma
Industry
Eligibility
Up to 18 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
22
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 29, 2026, 9:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Blood Flow Restriction and Creatine Supplementation in Women

NCT05877417
View directory record Official record
Conditions
Physical Inactivity
Interventions
Creatine Monohydrate, Blood Flow Restriction, Exercise
Dietary Supplement · Device · Other
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Oct 29, 2026, 9:23 PM EDT
Recruiting Phase 2 Interventional

LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

NCT05798923
View directory record Official record
Conditions
Pulmonary Hypertension Due to Lung Diseases and Hypoxia
Interventions
Placebo, LAM-001
Drug
Lead sponsor
IRulya Therapeutics Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
4
States / cities
Tucson, Arizona • New Haven, Connecticut • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 29, 2026, 9:23 PM EDT
Completed Phase 3 Interventional Results available

Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate and Fluticasone Propionate in People With Asthma

NCT01436110
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone furoate 50mcg, Fluticasone propionate 100mcg, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
20
States / cities
Los Angeles, California • Rolling Hills Estates, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 29, 2026, 9:23 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Absorption Kinetics of Polyphenols in Angel's Plant (Angelica Keiskei)

NCT00721643
View directory record Official record
Conditions
Oxidative Stress
Interventions
Angel's plant (Angelica keiskei)
Dietary Supplement
Lead sponsor
Tufts University
Other
Eligibility
60 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 29, 2026, 9:23 PM EDT
Completed Phase 3 Interventional Results available

Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations

NCT01120691
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
QVA149, NVA237, tiotropium, Salbutamol/albuterol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
2,224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
53
States / cities
Birmingham, Alabama • Fairhope, Alabama • Florence, Alabama + 46 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2013 · Synced Oct 29, 2026, 9:23 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Repeat Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects

NCT02289495
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK2838232, Placebo, Ritonavir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 29, 2026, 9:23 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of GlcNAc on Tear Production in NGLY1-CDDG

NCT05402345
View directory record Official record
Conditions
NGLY1 Deficiency
Interventions
GlcNAc-GlcN, Placebo
Drug · Other
Lead sponsor
Eva Morava-Kozicz
Other
Eligibility
1 Year to 60 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 29, 2026, 9:23 PM EDT
Completed Phase 2 Interventional Results available

Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis

NCT00811395
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Teriflunomide, Placebo (for teriflunomide), Interferon-β [IFN-β], Glatiramer Acetate [GA]
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 31, 2012 · Synced Oct 29, 2026, 9:23 PM EDT
Recruiting Phase 2 Interventional

Topical Probiotic Sinus Irrigations for Treating Chronic Sinusitis

NCT05427695
View directory record Official record
Conditions
Chronic Rhinosinusitis (Diagnosis)
Interventions
Lactobacillus sakei proBio65, Isotonic Saline Solution
Drug · Other
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 29, 2026, 9:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Study of PF-04991532 in Healthy Subjects

NCT01102673
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders
Interventions
PF-04991532, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 5, 2010 · Synced Oct 29, 2026, 9:23 PM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Efficacy and Safety of NT 201 (Botulinum Toxin) Compared With Placebo for the Treatment of Adult Participants With Essential Tremor in the Arm

NCT04766723
View directory record Official record
Conditions
Essential Tremor of the Upper Limb
Interventions
NT 201, Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
9
States / cities
Tampa, Florida • Omaha, Nebraska • Las Vegas, Nevada + 6 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 29, 2026, 9:23 PM EDT
Completed Phase 3 Interventional

Demonstrate Exubera Works As Well As Avandia When Added To Sulfonylurea + Metformin In Controlling Glucose

NCT00150410
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Inhaled insulin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
88
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2008 · Synced Oct 29, 2026, 9:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4004280 in Healthy Participants

NCT05163522
View directory record Official record
Conditions
HIV Infections
Interventions
VH4004280, Placebo, Midazolam
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Oct 29, 2026, 9:23 PM EDT
Completed Phase 2 Interventional

A Phase 2 Study of the Safety and Efficacy of a Tofimilast in Adult Patients With Chronic Obstructive Pulmonary Disease

NCT00219622
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tofimilast
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
23
States / cities
Phoenix, Arizona • Riverside, California • Clearwater, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2012 · Synced Oct 29, 2026, 9:23 PM EDT
Completed Phase 2 Interventional Results available

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

NCT00787761
View directory record Official record
Conditions
Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT
Biological · Drug · Procedure
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
Up to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 1, 2012 · Synced Oct 29, 2026, 9:23 PM EDT
Completed Phase 3 Interventional

Evaluation of the Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance

NCT03597516
View directory record Official record
Conditions
Lactose Intolerance
Interventions
RP-G28, Placebos
Drug
Lead sponsor
Ritter Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
557 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
35
States / cities
Birmingham, Alabama • Chula Vista, California • Huntington Park, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2019 · Synced Oct 29, 2026, 9:23 PM EDT
Not yet recruiting Phase 2 Interventional

A Clinical Trial of Resistant Potato Starch for Gut MDRO Decolonization

NCT07792915
View directory record Official record
Conditions
Clostridium Infections, Methicillin-resistant Staphylococcus Aureus (MRSA), Vancomycin-Resistant Enterococci, Carbapenem-Resistant Enterobacteriaceae, Asymptomatic Infections
Interventions
Resistant Potato Starch, Maltodextrin
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 29, 2026, 9:23 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF Episodes

NCT01777555
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
CVT-301, Placebo
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
30 Years to 80 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
13
States / cities
Little Rock, Arkansas • Boca Raton, Florida • Port Charlotte, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Oct 29, 2026, 9:23 PM EDT
Completed Phase 2 Interventional Results available

A Study of LY3209590 in Participants With Type 1 Diabetes

NCT04450407
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
LY3209590, Insulin Degludec
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
33
States / cities
Concord, California • Fresno, California • Ventura, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Oct 29, 2026, 9:23 PM EDT
Completed Phase 4 Interventional Results available

Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.

NCT01966107
View directory record Official record
Conditions
COPD, Chronic Obstructive Pulmonary Disease, Moderate to Very Severe COPD
Interventions
Aclidinium Bromide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
3,635 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
433
States / cities
Birmingham, Alabama • Florence, Alabama • Foley, Alabama + 334 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Oct 29, 2026, 9:23 PM EDT